Gefitinib
- PDF / 141,581 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 59 Downloads / 178 Views
1
Gefitinib Hepatotoxicity: 6 case reports Six women aged 41–89 years developed grade 1 or 2 hepatotoxicity during treatment with gefitinib [routes not stated] for non-small cell lung cancer. A 69-year-old woman began receiving gefitinib 250 mg/day. Four weeks later, her ALT level increased to 67.7 U/L and continued to increase with the continued administration of gefitinib, reaching a peak of 126.7 U/L. She also had an AST level of 77.2 U/L. She was diagnosed with grade 2 hepatotoxicity, and the dosage of gefitinib was decreased to 250mg every second day. Seven days later, her ALT and AST levels had decreased to 58.1 and 35.5 U/L, respectively. After the dosage of gefitinib was increased back to 250 mg/day, her ALT and AST levels increased to 122.0 and 67.4 U/L, respectively. The dosage of gefitinib was once again decreased to 250mg every second day, and her transaminase levels normalised. She continued to receive gefitinib 250mg every second day for a further 5 months, with no episodes of hepatotoxicity. The remaining five patients presented with mildly elevated transaminase levels 7 days to 6 months after starting gefitinib 250 mg/day. Peak ALT and AST levels ranged from 56.0–95.9 U/L and 35.5–76.9 U/L, respectively. They were diagnosed with grade 1 hepatotoxicity. Gefitinib was continued at the same dosage for a further 3–7 months, and their transaminase levels recovered after 4–11 months. Author comment: "After excluding other potential etiological factors for hepatotoxicity, we hypothesized that the hepatotoxicity in the 6 patients was induced by gefitinib." Chen J, et al. Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. Onkologie 35: 509-513, No. 9, Sep 2012. Available from: URL: http:/ 803080493 /dx.doi.org/10.1159/000341828 - China
0114-9954/10/1430-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 1 Dec 2012 No. 1430
Data Loading...
